Present new clinical data from the Phase I/II studies of AMT-130
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 22 Jun 2023
- Due
- 31 Dec 2023
- Delivered
- December 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“In the fourth quarter of 2023, uniQure expects to present new clinical data from the Phase I/II studies of AMT-130”
What we found
Evidence strength A What the grades mean
The company announced updated interim clinical data from its Phase I/II studies of AMT-130 in December 2023, fulfilling the commitment to present new data within the fourth quarter of 2023.
-
A uniQure N.V. 10-K filed 2024-02-28
“in December 2023, we announced updated interim data from our ongoing Phase I/II clinical trial of AMT-130” ✓ confirmed on the page
Market reaction: the shares moved -18.4% against the S&P 500 over the three sessions around the disclosure (27 Feb 2024 to 1 Mar 2024). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +639 days
- 4 versions
-
Version 1 · original · stated 22 Jun 2023
Deadline 31 Dec 2023 (“In the fourth quarter of 2023”) · wording expected
-
Version 2 · stated 19 Dec 2023
Deadline 30 Jun 2024 (“In mid-2024”) · wording expected
“In mid-2024, uniQure expects to present another clinical update from the ongoing Phase I/II studies of AMT-130, including additional follow-up data from the treated patients”
-
Version 3 · stated 9 Jul 2024
Deadline 30 Jun 2025 (“In mid-2025”) · wording expected
“In mid-2025, uniQure expects to present another interim analysis from the ongoing Phase I/II studies of AMT-130.”
-
Version 4 · stated 27 Feb 2025
Deadline 30 Sep 2025 (“In the third quarter of 2025”) · wording expected
“In the third quarter of 2025, the Company expects to present data from its ongoing Phase I/II studies of AMT-130 in support of a potential BLA submission.”
-
Version 5 · stated 5 May 2026
Deadline 19 Jun 2026 (“June 18 -19, 2026”)
“provide data from the first cohort of six patients in the Phase I/IIa study with up to six months of follow-up at the Epilepsy Foundation Pipeline Conference, June 18 -19, 2026”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Present
- Deliverable
- Clinical data from Phase I/II studies
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-QURE-001839 · Corrections policy